Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL ® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including all-cause otolaryngologist,
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021 .
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 28, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital
September 14, 2021–Alexandria, Virginia —The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better
MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 6, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021 .
Acquisition to Add Innovative Bioabsorbable Drug Release Platform to Chronic Rhinosinusitis Portfolio DUBLIN and MENLO PARK, Calif. , Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with
VenSure and Cube Join the Company’s Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat CRS MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 26, 2021-- Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 23, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021 .
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 22, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced preliminary second quarter 2021 revenue and provided a business update.
Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries MENLO PARK, Calif. --(BUSINESS WIRE)--May 20, 2021-- Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming
